Shattuck Labs, Inc. (STTK) company profile

The company is a clinical-stage biotechnology company focused on developing therapies for inflammatory and immune-mediated diseases. It specializes in protein engineering to discover and advance monoclonal and bispecific antibodies that target the Death Receptor 3 (DR3) pathway. Its lead investigational product candidate is SL-325, a DR3-blocking monoclonal antibody intended to treat conditions such as inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. In addition, the pipeline includes SL-425, an extended half-life version of its primary candidate, alongside multiple preclinical bispecific antibodies designed to simultaneously inhibit DR3 and other biologically relevant disease pathways.

The business operates as a research and clinical-stage development enterprise without commercialized products or proprietary manufacturing plants. It contracts bulk drug substance production to a single third-party contract development and manufacturing organization, Kemwell Biopharma Private Limited. The provided text does not disclose the company's specific headquarters location, overall employee headcount, founding details, or official corporate website.

Summary of the business section of Shattuck Labs's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $17.00 per share of common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we employed 40 full-time employees at two locations in the United States, in Austin, TX and Durham, NC.”